TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04399213

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 50 µg Histamine
Description: Skin prick through 50 µg/5 µL histamine diHCl

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 50 µg Histamine
Description: Skin prick through 50 µg/5 µL histamine diHCl

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 50 µg Histamine
Description: Skin prick through 50 µg/5 µL histamine diHCl

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 15 µg Histamine
Description: Skin prick through 15 µg/5 µL histamine diHCl

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 15 µg Histamine
Description: Skin prick through 15 µg/5 µL histamine diHCl

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 15 µg Histamine
Description: Skin prick through 15 µg/5 µL histamine diHCl

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 5 µg Histamine
Description: Skin prick through 5 µg/5 µL histamine diHCl

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 5 µg Histamine
Description: Skin prick through 5 µg/5 µL histamine diHCl

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 5 µg Histamine
Description: Skin prick through 5 µg/5 µL histamine diHCl

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Placebo (saline)
Description: Skin prick through 5 µL saline (0.9% NaCl)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Placebo (saline)
Description: Skin prick through 5 µL saline (0.9% NaCl)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Placebo (saline)
Description: Skin prick through 5 µL saline (0.9% NaCl)
Study: NCT01710202

Intervention type: DRUG
Intervention: Hydrocortisone
Description: Each subject in this group will receive one 20mg hydrocortisone capsule to be taken by mouth.
Study: NCT00497393

Intervention type: BEHAVIORAL
Group type: NO_INTERVENTION
Intervention: Clinical Decision Unit
Description: a dedicated 2-bed area to see patients and then rotate them back into the waiting room area for labs and diagnostic imaging.
Study: NCT04160234

Intervention type: OTHER
Intervention: web-based questionnaires
Description: Patients will be asked to complete web-based questionnaires on a tablet computer
Study: NCT02046590

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: General anesthesia
Study: NCT01262222

Intervention type: OTHER
Intervention: endothelial function testing
Description: After obtaining informed consent, eligible patients will undergo endothelial function testing using the Endo-PAT 2000 (Itamar Medical) device. This PAT device applied to the finger tip will be used to measure change in blood flow in one arm at rest and after a 5 minute occlusion of the brachial artery with a blood pressure cuff. The other arm will serve as the patient's own control. After the cuff is deflated, blood flow normally increases in the arm for a period of time (flow mediated dilatation). In patients with abnormal endothelial function, this increase in blood flow is damped. The ratio of flow in the ischemic finger to the nonischemic finger (RH-PAT) will then be correlated with postoperative cardiac events.
Study: NCT01435304

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: method of returning residual CPB blood ( Hemobag®)
Description: The Hemobag® is a collection reservoir used to facilitate ultrafiltration of the CPB circuit after the patient has been disconnected from CPB).
Study: NCT02992236

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: VAS203
Description: Infusion of NO-Synthase inhibitor VAS203

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Infusion of saline
Study: NCT00984893

Intervention type: DRUG
Intervention: zoledronic acid

Intervention type: DRUG
Intervention: Any oral bisphosphonates marketed in Canada
Study: NCT03596112

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: application of a polyacrylate wound pad
Description: A sterile polyacrylate wound pad with activated carbon cloth treatment will be applied to chronic wounds in an outpatient clinic from a specialist nurse

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocellular foam
Description: Active Comparator: hydrocellular foam pad serile hydrocellular standard foam pad will be applied to chronic wounds in an outpatient clinic from a specialist nurse
Study: NCT02861222

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Study: NCT01385969

Intervention type: DEVICE
Intervention: Standard inflation of LMA cuff
Description: LMA cuff will be inflated per standard practice with a syringe and resulting cuff pressure will be measured by manual palpation of the cuff per standard practice.

Intervention type: DEVICE
Intervention: Pressure check with syringe recoil
Description: LMA cuff will be inflated per standard practice with a syringe and resulting cuff pressure will be measured by syringe recoil

Intervention type: DEVICE
Intervention: Pressure check by pressure transducer
Description: LMA cuff will be inflated per standard practice with a syringe and resulting cuff pressure will be measured by pressure transducer.
Study: NCT06753630

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Extensor Muscle Strengthening Exercise
Description: A series of exercises aimed at strengthening the extensor muscles of the forearm to alleviate symptoms of lateral epicondylitis.
Study: NCT03346772

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza vaccination
Description: Adults will receive one intramuscular dose of seasonal quadrivalent inactivated influenza vaccine, as indicated for standard of care.
Study: NCT01091506

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo once a day for 12 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: L-methylfolate
Description: L-methylfolate 15mg once a day for 12 weeks
Study: NCT03095144

Intervention type: DEVICE
Intervention: Spinal anesthesia
Description: Pyloromyotomy under spinal anesthesia

Intervention type: DEVICE
Intervention: General anesthesia
Description: Pyloromyotomy under general anesthesia
Study: NCT03258918

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low-Carbohydrate Diabetes Prevention Program
Description: LC-DPP participants will be instructed to follow ad-libitum very low-carbohydrate, ketogenic diet, which restricts carbohydrate intake (not including fiber) to 20-35 grams per day with the goal of achieving nutritional ketosis. Participants will be encouraged to eat a normal amount of protein (roughly 80-120 grams per day) and to derive the remaining calories from fat. Allowable foods include: meats, fish, poultry, eggs, cheese, seeds, nuts, leafy greens, non-starchy vegetables, and some fruits.
Study: NCT02718833

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elotuzumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Study: NCT00806273

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vista Ultrasonic Bleach Bypass System
Description: The ultrasonic needle will be activated by depressing the foot pedal which will begin the debridement process. Irrigants will be delivered constantly at the recommended rate via the syringe pump and the needle tip will be moved up and down with a 2mm amplitude for the entire 1 minute activation cycle, which will deliver a total of 3ml of irrigant. The ultrasonic unit will be turned off and the needle will be withdrawn from the canal.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Needle Irrigation
Description: irrigation with 3ml 6% NaOCl is performed moving the needle from just short of binding to 2mm coronal in constant motion for 60 seconds and left untouched in a full canal for 60 seconds.
Study: NCT04630691

Intervention type: PROCEDURE
Intervention: Implantation
Description: Patients received narrow diameter implants in posterior mandible or maxilla

Intervention type: PROCEDURE
Intervention: Implantation
Description: Patients received narrow diameter implants in posterior mandible or maxilla
Study: NCT05202067

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: pharmaceutical education
Description: The patients who were assigned to the intervention group will receive a didactic talk from the research pharmacist. In addition, the patient will be given an updated list of their prescribed medications on a wallet card.
Study: NCT03378674

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil Injectable Product
Description: remifentanil: 0,15 mcg/kg/min

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil Injectable Product
Description: remifentanil: 0,15 mcg/kg/min
Study: NCT01163851

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 4 mg/kg
Description: RN316 10 mg/ml vial sd. Infusion based on weight Infusion duration = 60 minutes.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg
Description: RN316 10 mg/ml vial sd. Infusion based on weight Infusion duration = 60 minutes.
Study: NCT02705300

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Irinotecan 165 mg/m2 iv
Description: Max. 4 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan 165 mg/m2 iv
Description: Max. 4 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxaliplatin 85 mg/m2 iv
Description: Max. 4 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin 85 mg/m2 iv
Description: Max. 4 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Calcium folinate 200 mg/m2 iv
Description: Max. 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium folinate 200 mg/m2 iv
Description: Max. 6 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 5-fluorouracil 3200 mg/m2
Description: Max. 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil 3200 mg/m2
Description: Max. 6 months

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Tocotrienol
Description: Max. 2 years or at the discretion of the investigator
Study: NCT06753630

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Extensor Muscle Strengthening Exercise
Description: A series of exercises aimed at strengthening the extensor muscles of the forearm to alleviate symptoms of lateral epicondylitis.
Study: NCT02705300

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Max. 2 years or at the discretion of the investigator
Study: NCT06753630

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Extracorporeal Shockwave Therapy
Description: A non-invasive procedure that uses shockwaves to promote healing and reduce pain in the affected area.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extracorporeal Shockwave Therapy
Description: A non-invasive procedure that uses shockwaves to promote healing and reduce pain in the affected area.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline injection (Octreotide LAR placebo)
Description: A 3mL injection of saline solution used as a placebo in the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polydeoxyribonucleotide Injection
Description: A 3mL injection of polydeoxyribonucleotide (5.625mg/3mL) used to enhance the healing process and improve outcomes in lateral epicondylitis treatment.
Study: NCT00321698

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy (IMRT)
Description: Group 1=radiation only; All men in all Arms/Groups receive same radiation treatment protocol. External Beam, 45 Gy (1.8 Gy fractions), 5 per week (daily) x 5 weeks (25 fractions)
Study: NCT06755437

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rehabilitation with a computerized device (in the morning)
Description: Each group received face-to-face cognitive rehabilitation with the electronic device for 45 min. The exercises were selected by the therapist and divided into four sessions of 2 to 3 days each. Each session included 40 min of activity and 5 minute of break

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation with a computerized device (in the morning)
Description: Each group received face-to-face cognitive rehabilitation with the electronic device for 45 min. The exercises were selected by the therapist and divided into four sessions of 2 to 3 days each. Each session included 40 min of activity and 5 minute of break
Study: NCT00321698

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel+IMRT
Description: Group 2=IV over 30mins, 10mg/m2; weekly x 5 weeks starting on day one of radiation; Group 3=IV over 30mins, 20mg/m2; weekly x 5 weeks starting on day one of radiation; Group 4=IV over 30mins, 30mg/m2; weekly x 5 weeks starting on day one of radiation; Phase II with no phase I dose-limiting toxicities=IV over 30mins, 30mg/m2; weekly x 5 weeks starting on day one of radiation~Radiation: All men receive same radiation treatment protocol. External Beam, 45 Gy (1.8 Gy fractions), 5 per week (daily) x 5 weeks (25 fractions)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel+IMRT
Description: Group 2=IV over 30mins, 10mg/m2; weekly x 5 weeks starting on day one of radiation; Group 3=IV over 30mins, 20mg/m2; weekly x 5 weeks starting on day one of radiation; Group 4=IV over 30mins, 30mg/m2; weekly x 5 weeks starting on day one of radiation; Phase II with no phase I dose-limiting toxicities=IV over 30mins, 30mg/m2; weekly x 5 weeks starting on day one of radiation~Radiation: All men receive same radiation treatment protocol. External Beam, 45 Gy (1.8 Gy fractions), 5 per week (daily) x 5 weeks (25 fractions)
Study: NCT02173002

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: myIBDcoach

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Study: NCT00534781

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: plasma microdebrider
Description: Coblation of the Achilles

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mechanical Surgical Debridement
Description: Surgical Debridement of the Achilles
Study: NCT03713060

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Mixed meal test
Description: All women will have mixed meal test, continous glucose monitoring and antenatal ultrasounds performed. The children born of these women will have DXA-scans performed after birth.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Mixed meal test
Description: All women will have mixed meal test, continous glucose monitoring and antenatal ultrasounds performed. The children born of these women will have DXA-scans performed after birth.
Study: NCT02983188

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Berberine
Description: Berberine tablets, 0.3g every time, two times daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebo tablets, 0.3g every time, two times daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antipsychotic Agents
Description: Antipsychotic agents prescribed at the discretion of the patients' psychiatrists with respect to patients' conditions. Concomitant use of other psychotropic drugs, including antidepressants, anxiolytics, and mood stabilizers for mood disorders, benzodiazepines and non-benzodiazepines for insomnia, and anticholinergics for extrapyramidal symptoms, was allowed as usual. For those who were under anti-hyperlipidemic, antihypertensive and anti-diabetic treatment, they were allowed to continue their current medications throughout the study.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Antipsychotic Agents
Description: Antipsychotic agents prescribed at the discretion of the patients' psychiatrists with respect to patients' conditions. Concomitant use of other psychotropic drugs, including antidepressants, anxiolytics, and mood stabilizers for mood disorders, benzodiazepines and non-benzodiazepines for insomnia, and anticholinergics for extrapyramidal symptoms, was allowed as usual. For those who were under anti-hyperlipidemic, antihypertensive and anti-diabetic treatment, they were allowed to continue their current medications throughout the study.
Study: NCT04065984

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Microstim 2v2 Stimulator
Description: Neuro-muscular electrical stimulator portable device (9v battery) connected to the skin participant over the muscle body of choice using self adhesive electro-gel pads. Treatment devices and placebo devices.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microstim 2v2 Stimulator
Description: Neuro-muscular electrical stimulator portable device (9v battery) connected to the skin participant over the muscle body of choice using self adhesive electro-gel pads. Treatment devices and placebo devices.
Study: NCT00002924

Intervention type: OTHER
Intervention: mutation analysis
Study: NCT03466463

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: GNT0003
Description: Intravenous infusion, single dose
Study: NCT02416609

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: LDR
Description: LDR will be delivered during each cycle of Gem-based doublets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gem-based doublets
Description: 4 cycles of Gem-based doublets

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: SBRT will be administered after the fourth Gem-based doblet cycle, if no progression; three fractions will be administered
Study: NCT06755437

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Self-treatment with a computerized device (in the afternoon)
Description: In the afternoon, the experimental group performed 60 min. self-guided treatment with the electronic device.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: self-treatment with pencil-and-paper exercises (in the afternoon)
Description: In the afternoon, the control group performed 60 min of cognitive self-treatment with conventional paper-and-pencil instruments. The therapist created a variety of exercises every day
Study: NCT01488383

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Purified extract of Rebaudina Stevia-Stevioside
Description: volunteers will take only one capsule of stevioside (one day), and then corresponding measurements will be performed.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium saccharin
Description: Volunteers will take one capsule of saccharin 250mg (one day) and then, corresponding measurements will be performed
Study: NCT00820053

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epirubicin and lipiodol
Description: using the technology of Seldinger,The drugs (30 mg epirubicin mixed with 5 ml lipiodol) are given via hepatica propria artery.
Study: NCT01158846

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prasugrel/bivalirudin
Description: 60mg loading dose followed by 10mg or 5 mg (according to body weight or age)maintenance dose of prasugrel. Bivalirudin during the primary PCI (bolus plus infusion)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clopidogrel/abciximab
Description: 600mg loading dose of clopidogrel followed by 75mg maintenance dose. Abciximab will be used during primary PCI, bolus plus infusion.
Study: NCT04754828

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Assigned to a rounding style
Description: Team rounded on new admissions either in hallway or at the bedside

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Assigned to a rounding style
Description: Team rounded on new admissions either in hallway or at the bedside
Study: NCT04468347

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flortaucipir F18
Description: IV injection, 240 megabecquerel (MBq) (6.5 mCi)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flortaucipir F18
Description: IV injection, 240 megabecquerel (MBq) (6.5 mCi)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flortaucipir F18
Description: IV injection, 240 megabecquerel (MBq) (6.5 mCi)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flortaucipir F18
Description: IV injection, 240 megabecquerel (MBq) (6.5 mCi)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Brain PET scan
Description: positron emission tomography (PET) scan of the brain

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Brain PET scan
Description: positron emission tomography (PET) scan of the brain

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Brain PET scan
Description: positron emission tomography (PET) scan of the brain

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Brain PET scan
Description: positron emission tomography (PET) scan of the brain
Study: NCT02713932

Intervention type: DEVICE
Intervention: Transcatheter aortic valve implantation
Study: NCT04120649

Intervention type: PROCEDURE
Intervention: hysterectomy
Description: total hysterectomy, bilateral salpingo-oopherectomy (based on the age of the patient), pelvic and para-aortic lymphadenectomy, and peritoneal washings
Study: NCT06755905

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ICGL-guided treatment
Description: Indocyanine green lymphography guided resection combined with sclerotherapy
Study: NCT03948412

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Closed Incision Negative Pressure Wound Therapy (Prevena)
Description: Closed Incision Negative Pressure Wound Device (Prevena) applied to closed wound at completion of operation.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control - Standard Dressings
Description: Standard wound dressings applied to closed wound at completion of operation.
Study: NCT02099617

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous Coronary Intervention (PCI) with short DAPT duration with Synergy II stent

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous Coronary Intervention (PCI) with short DAPT duration with Omega stent

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous Coronary Intervention (PCI) with short DAPT duration with Rebel stent
Study: NCT01741688

Intervention type: BIOLOGICAL
Intervention: Tocilizumab
Description: Tocilizumab was administered according to the local label.
Study: NCT01323387

Intervention type: DEVICE
Group type: OTHER
Intervention: Interbody Fusion
Description: allograft spacer + anterior plate